LONDON, March 9, 2016 /PRNewswire/ -- Summary
DelveInsight's PD-1 and PD-L1 inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2016 gives an insight on the PD-1 and PD-L1 inhibitors, which are amongst the highly growing fields in biopharmaceutical industry. Most of these immunotherapeutic are being used in Oncology. There are 45 drugs in pipeline with approximate 245 active clinical studies.
The report provides an update on the recent collaborations occurring in the PD-1 and PDL-1 market and the companies looking for partnership for the same. Report also covers Commercial Aspects such as the Current and Future Market, Barriers and challenges and SWOT analysis. Future competitive landscape of PD-1 and PD-L1 inhibitors is estimated to be very strong. It analyses PD-1 and PD-L1 industry and discusses the key market trends, major players, Key technologies.
- Overview of PD-1 and PD-L1 inhibitors, role, significance, pathway, mechanism of action (MoA) and biomarkers of PD-1 and PD-L1 inhibitors
- The new report has covered the worldwide market of PD-1 and PD-L1 inhibitors, information of marketed molecules including along with patent expiry and impact on market after expiry and detail profiling of Pipeline assets
- It also includes Indication wise detailed epidemiology along with trends in epidemiology, incidence and prevalence segmented in to major geographies
- Key topics covered include strategic competitor assessment, market characterization, opportunities, barriers and challenges in the market along with SWOT analysis of the PD-1 and PD-L1 inhibitors market
- Pipeline analysis: Comprehensive data split across different phases and emerging trends and comparative analysis of marketed and pipeline molecules, pipeline molecules with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with latest updates
- Analysis of the current and future market competition in the global PD-1 and PD-L1 inhibitors drug market. Current scenario of market with upcoming blockbuster molecules and their impact on overall market.
Reasons to Buy
- The report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for PD-1 and PD-L1 inhibitors.
- Develop business strategies by understanding the trends shaping and driving for Immunotherapeutics market
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding PD-a and PD-L1 inhibitors pipeline in-depth
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners to enhance and expand business potential and scope
- Identifying the upcoming leaders in the PD-1 and PD-L1 inhibitors market in the coming years.
Download the full report: https://www.reportbuyer.com/product/2880499/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers